{"brief_title": "Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)", "brief_summary": "The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).", "condition": ["Lymphoma, Non-Hodgkin"], "intervention_type": ["Drug"], "intervention_name": ["TRAIL-R1 mAb (TRM-1; HGS-ETR1)"], "criteria": "Primary Inclusion Criteria: - Relapsed or refractory histologically confirmed Non-Hodgkin's Lymphoma - Previously treated with at least 1 therapeutic regimen and relapsed or progressed or failed to achieve a response after the last regimen - 18 years of age or older Primary Exclusion Criteria: - Received a non-FDA approved investigational agent within the last 4 weeks - Received cancer therapies (chemotherapy, biological therapy [including hormonotherapy], radiation therapy or immunosuppressants within the last 3 weeks, 8 weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea - Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous HSCT within the last 16 weeks - Prior history of an allogeneic HSCT - HIV, AIDS-related lymphoma, central nervous system (CNS) lymphoma, Hepatitis-B or Hepatitis-C - Infection requiring antibiotics within the last 4 weeks - Major surgery within the last 4 weeks - Pregnant or breast-feeding women - History of other cancers within the past 5 years", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Lymphoma", "Lymphoma, Non-Hodgkin", "Antibodies", "Antibodies, Monoclonal"], "id": "NCT00094848"}